Biosimilar Switch
Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the therapeutic management of inflammatory rheumaticdiseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.
- Reasons of Switching
- Immunogenicity
- Switching of bDMARD to its Biosimilars
- Switches in Clinical Trails